8 | | CHRNA3 | 'induced pluripotent stem cell' vs 'fibroblast of dermis' in 'normal' | cell type, disease | Klinefelter syndrome derived hiPSCs show similar XCI behavior as female hPSCs |
7.4 | | CHRNA3 | 'induced pluripotent stem cell' vs 'fibroblast of dermis' in 'Klinefelter's syndrome' | cell type, disease | Klinefelter syndrome derived hiPSCs show similar XCI behavior as female hPSCs |
5.4 | | CHRNA3 | 'doxycycline; 0.5 microgram per milliliter; Day 4 post Neurogenin induction' vs 'control' | compound, treatment | Rapid neurogenesis through transcriptional activation in human stem cell (RNA-Seq) |
4.7 | | CHRNA3 | 'doxycycline; 0.5 microgram per milliliter; Day 1 post Neurogenin induction' vs 'control' | compound, treatment | Rapid neurogenesis through transcriptional activation in human stem cell (RNA-Seq) |
4.6 | | CHRNA3 | 'doxycycline; 0.5 microgram per milliliter; Day 3 post Neurogenin induction' vs 'control' | compound, treatment | Rapid neurogenesis through transcriptional activation in human stem cell (RNA-Seq) |
-4.5 | | CHRNA3 | 'estrogen receptor alpha shRNA' vs 'scrambled shRNA' | RNA interference | RNA-seq of the human breast cancer ERα-suppressed MCF-7(MCF-7/SP10+) cells and of their internal control MCF-7 (MCF-7/C) cells |
-4.4 | | CHRNA3 | 'Mycobacterium tuberculosis' vs 'none' in 'infant' | developmental stage, infect | Multifaceted dysfunction of infant airway macrophages in response to Mycobacterium tuberculosis |
4.3 | | CHRNA3 | 'valproic acid; 15 millimolar' vs 'control' at '3 day' | compound, sampling time point | RNA-seq of Primary Human Hepatocytes (PHH) exposed to Valproic Acid (VPA) for 3 days daily and 3 days daily exposure followed by 3 days washout. |
-4 | | CHRNA3 | 'pancreatic adenocarcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-3.9 | | CHRNA3 | 'breast carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-3.9 | | CHRNA3 | 'Neurobasal medium' vs 'DMEM/F12 with glutamax' | growth condition | RNA sequencing of human iPSC-derived brain microvascular endothelial cells. |
3.5 | | CHRNA3 | 'valproic acid; 15 millimolar' vs 'control' at '1 day' | compound, sampling time point | RNA-seq of Primary Human Hepatocytes (PHH) exposed to Valproic Acid (VPA) for 3 days daily and 3 days daily exposure followed by 3 days washout. |
3.4 | | CHRNA3 | '1 day' vs '0 day' | time | RNA-Seq characterization of human H1-derived NPC differentiation timecourse |
3.4 | | CHRNA3 | 'P0 cells' vs 'untreated P4 cells' | passage, treatment | Transcription profiling by high throughput sequencing of human fetal differentiated P0 retinal pigment epithelial cells, mesenchymal P4 cells, and A-83-01 rescued P4 cells |
-3.4 | | CHRNA3 | 'colorectal cancer metastatic in the liver' vs 'normal' | biopsy site | RNA-seq of 54 samples (normal colon, primary tumor, and liver metastases) from 18 colorectal cancer patients |
-3.3 | | CHRNA3 | 'colorectal carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
3.2 | | CHRNA3 | 'trichostatin A; 500 nanomolar' vs 'control' | compound | Transcription profiling by high throughput sequencing of human aortic endothelial cell treated with TSA |
-3.1 | | CHRNA3 | 'human intestinal organoids derived from H9 stem cells' vs 'Undifferentiated H9 Stem Cells' | cell type | Transcriptional Profiling of human pluripotent stem cells and and derived tissues |
3.1 | | CHRNA3 | 'induced pluripotent stem cell' vs 'cardiac muscle cell' | cell type | Gene expression profiling by RNA-seq of human iPSC and iPSC-derived cardiomyocytes from an Yoruban individual (NA19101) |
3 | | CHRNA3 | 'valproic acid; 15 millimolar' vs 'control' at '2 day' | compound, sampling time point | RNA-seq of Primary Human Hepatocytes (PHH) exposed to Valproic Acid (VPA) for 3 days daily and 3 days daily exposure followed by 3 days washout. |
3 | | CHRNA3 | 'MEF2D-HNFNPUL1 knockdown by siRNA' vs 'luciferase siRNA' | RNA interference | RNA-seq for gene expression changes upon silencing MEF2D-fusion in a MEF2D-HNRNPUL1 fusion-expressing Kasumi-7 cell line |
3 | | CHRNA3 | 'suberoylanilide hydroxamic acid' vs 'control' | compound | Vascular histone deacetylation by pharmacological HDAC inhibition [SAHA, RNA-seq] |
2.8 | | CHRNA3 | 'lung cancer' vs 'normal' in 'lung; Formalin-fixed paraffin-embedded tissue' | disease, organism part, protocol | Transcription profiling by array of formalin-fixed paraffin-embedded or fresh frozen human tumor samples |
-2.8 | | CHRNA3 | 'paediatric' vs 'foetal' in 'epithelial cell of large intestine' | cell type, developmental stage | Transcriptional profiling by array of intestinal epithelial cells from foetal and paediatric gut |
2.7 | | CHRNA3 | 'doxorubicin; 0.6 microgram per milliliter' vs 'none' | compound | Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells (Affymetrix) |
-2.7 | | CHRNA3 | 'primary tumor' vs 'adjacent non-tumor colon' in 'colorectal cancer' | disease, sampling site | RNA-seq of colorectal cancer primary tumor and adjacent colon tissue |
2.7 | | CHRNA3 | 'neoplasm' vs 'normal tissue adjacent to neoplasm' | sampling site | Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma |
2.7 | | CHRNA3 | 'small cell lung carcinoma' vs 'normal' | disease | RNA-seq of primary tumors from 79 small cell lung cancer patients and 7 normal lung tissue |
2.6 | | CHRNA3 | '11 day' vs '0 day' | time | RNA-Seq characterization of human H1-derived NPC differentiation timecourse |
-2.5 | | CHRNA3 | 'fibroblast growth factor 2' vs 'control' | compound | Transcription profiling by high throughput sequencing of human polarized cerebellar plate neuroepithelium in three-dimensional culture |
-2.5 | | CHRNA3 | 'hepatobiliary carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
2.4 | | CHRNA3 | '36 hour' vs '24 hour' in 'embryonic stem cell differentiating toward definitive endoderm' | cell type, time | RNA-seq of definitive endoderm differentiation of human embryonic stem cells in early G1 phase of the cell cycle |
-2.4 | | CHRNA3 | 'JQ1 (1 micromolar) and THZ1 (35 nanomolar)' vs 'none' | compound | RNA-seq of IMR-5/75 neuroblastoma cell line treated with JQ1, THZ1 or combination against untreated controls |
-2.4 | | CHRNA3 | 'HES1 and NEUROG3 homozygous double knockout' vs 'wild type genotype' | genotype | RNA-seq of Human Embryonic Stem Cell derived pancreas progenitor differentiation, Day 13 of wildtype, HES1-/-, NEUROG3-/- and HES1-/-NEUROG3-/- genotypes |
-2.4 | | CHRNA3 | 'paediatric' vs 'foetal' in 'epithelial cell of small intestine' | cell type, developmental stage | Transcriptional profiling by array of intestinal epithelial cells from foetal and paediatric gut |
-2.4 | | CHRNA3 | 'tumor' vs 'normal' | clinical information | Transcription profiling by high throughput sequencing in esophageal squamous cell carcinoma cells. |
2.4 | | CHRNA3 | 'erythroleukemia; ZRSR2 shRNA' vs 'normal' | disease, genotype | RNA-seq of bone marrow from patients with myelodysplastic syndrome |
-2.3 | | CHRNA3 | 'Mycobacterium tuberculosis' vs 'none' in 'adult' | developmental stage, infect | Multifaceted dysfunction of infant airway macrophages in response to Mycobacterium tuberculosis |
-2.3 | | CHRNA3 | 'familial hemophagocytic lymphohistiocytosis 5' vs 'normal' | disease | RNAseq on PBMC of three patients with Familial Hemophagocytic Lymphohistiocytosis Type 5 (FHL5) and three age and sex-matched controls |
-2.3 | | CHRNA3 | 'non-triple-negative breast cancer; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
-2.2 | | CHRNA3 | '501Mel; shBRG1 knockdown' vs '501Mel; control' | cell line, phenotype | BRG1 recruitment by transcription factors MITF and SOX10 defines a specific configuration of regulatory elements in the melanocyte lineage (RNA-seq) |
2.2 | | CHRNA3 | 'human cytomegalovirus (Towne strain)' vs 'none' | infect | RNAseq of proneural glioblastoma stem-like cells 72 hours after infection with human cytomegalovirus (CMV) Towne strain |
2.2 | | CHRNA3 | 'squamous cell carcinoma' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
2.1 | | CHRNA3 | 'Crispr-mediated SOX4 knockout' vs 'wild type genotype' in 'none' at '0 hour' | genotype, infect, time | RNA-Seq of SOX4 and HOXD3 CRISPR KO SupT1 cells against wildtype SupT1 cells during HIV-1 infection |
-2 | | CHRNA3 | 'JQ1 (1 micromolar)' vs 'none' | compound | RNA-seq of IMR-5/75 neuroblastoma cell line treated with JQ1, THZ1 or combination against untreated controls |
2 | | CHRNA3 | 'sebaceous of Jadassohn nevus' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
2 | | CHRNA3 | 'CCRF-CEM; acute lymphoblastic (T-ALL) leukemia; P04' vs 'CCRF-CEM; acute lymphoblastic (T-ALL) leukemia; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
-2 | | CHRNA3 | 'lipopolysaccharide' vs 'none' in 'systemic-onset juvenile idiopathic arthritis' | disease, stimulus | A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis [RNA-Seq] |
2 | | CHRNA3 | '12 hour' vs '0 hour' in 'MCF-10A' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
-2 | | CHRNA3 | 'PLX4720; 1 micromolar' vs 'none' | compound | RNA-seq of the human melanoma cell-line A375P treated with the BRAF inhibitor PLX4720 and a DMSO control |
2 | | CHRNA3 | 'sulforaphane; prostate carcinoma' at '6 hour' vs 'sulforaphane; normal' at '6 hour' | compound, disease, time | Genome-wide transcriptome analysis of the dietary chemopreventive phytochemical sulforaphane on normal and prostate cancer cells. |
1.9 | | CHRNA3 | 'embryonic stem cell differentiating toward definitive endoderm; 36 hour' vs 'embryonic stem cell; 0 hour' | cell type, time | RNA-seq of definitive endoderm differentiation of human embryonic stem cells in early G1 phase of the cell cycle |
-1.9 | | CHRNA3 | 'A-83-01 rescued P4 cells' vs 'P0 cells' | passage, treatment | Transcription profiling by high throughput sequencing of human fetal differentiated P0 retinal pigment epithelial cells, mesenchymal P4 cells, and A-83-01 rescued P4 cells |
1.9 | | CHRNA3 | 'injected in NSG mouse' vs 'none' in 'none' | stimulus, xenograft | RNA-Seq of T cells sorted from human PBMCs, or from T cells stimulated with CD3/CD28 beads for 4 days, or from the spleen of NSG or NSG-HLA-A2/HHD mice, 7 days after transplantation with human PBMCs |
1.9 | | CHRNA3 | 'injected in NSG-HLA-A2/HHD mouse' vs 'none' in 'none' | stimulus, xenograft | RNA-Seq of T cells sorted from human PBMCs, or from T cells stimulated with CD3/CD28 beads for 4 days, or from the spleen of NSG or NSG-HLA-A2/HHD mice, 7 days after transplantation with human PBMCs |
1.9 | | CHRNA3 | 'NSAID-exacerbated respiratory disease' vs 'normal' | disease | Total RNAseq of human healthy control inferior turbinate and glucocorticoid-treated, NSAID-exacerbated respiratory disease (N-ERD) nasal polyp nasal brushings |
-1.9 | | CHRNA3 | 'lapatinib; 500 nanomolar; 7 day' vs 'dimethyl sulfoxide; 1 day' | compound, time | RNA-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib |
1.8 | | CHRNA3 | 'Crispr-mediated SOX4 knockout' vs 'wild type genotype' in 'HIV-1' at '18 hour' | genotype, infect, time | RNA-Seq of SOX4 and HOXD3 CRISPR KO SupT1 cells against wildtype SupT1 cells during HIV-1 infection |
1.8 | | CHRNA3 | '3 to 5 weeks post ovulation' vs 'adult' in 'normal' | developmental stage, disease | Comparison of gene expression profiling of human lung at four developmental stages and lung adenocarcioma |
1.8 | | CHRNA3 | 'CCRF-CEM; acute lymphoblastic (T-ALL) leukemia; P01' vs 'CCRF-CEM; acute lymphoblastic (T-ALL) leukemia; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
-1.8 | | CHRNA3 | 'Hermes 3A; shMITF knockdown' vs 'Hermes 3A; control' | cell line, phenotype | BRG1 recruitment by transcription factors MITF and SOX10 defines a specific configuration of regulatory elements in the melanocyte lineage (RNA-seq) |
1.8 | | CHRNA3 | 'lung cancer' vs 'normal' in 'lung; Fresh-frozen tissue' | disease, organism part, protocol | Transcription profiling by array of formalin-fixed paraffin-embedded or fresh frozen human tumor samples |
-1.8 | | CHRNA3 | 'Crohn's disease; B2, stricturing' vs 'non inflammatory bowel disease control' | disease, disease staging | mRNA and small RNA associated with Crohn's disease behavior [RNA-Seq] |
1.7 | | CHRNA3 | 'Crispr-mediated SOX4 knockout' vs 'wild type genotype' in 'HIV-1' at '30 hour' | genotype, infect, time | RNA-Seq of SOX4 and HOXD3 CRISPR KO SupT1 cells against wildtype SupT1 cells during HIV-1 infection |
1.7 | | CHRNA3 | 'lung carcinoma' vs 'normal' | biopsy site, disease | Gene expression profiling of the adjacent airway field cancerization in early stage NSCLC |
1.7 | | CHRNA3 | '200 nanomolar; retinoic acid' vs '1 micromolar DMSO' | compound | Transcription profiling by array of human embryonic stem cells response to retinoic acid exposure |
1.7 | | CHRNA3 | 'actinic keratosis' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
1.7 | | CHRNA3 | 'DMSO; prostate carcinoma' at '6 hour' vs 'DMSO; normal' at '6 hour' | compound, disease, time | Genome-wide transcriptome analysis of the dietary chemopreventive phytochemical sulforaphane on normal and prostate cancer cells. |
1.6 | | CHRNA3 | 'Crispr-mediated SOX4 knockout' vs 'wild type genotype' in 'HIV-1' at '42 hour' | genotype, infect, time | RNA-Seq of SOX4 and HOXD3 CRISPR KO SupT1 cells against wildtype SupT1 cells during HIV-1 infection |
1.6 | | CHRNA3 | 'Crispr-mediated SOX4 knockout' vs 'wild type genotype' in 'HIV-1' at '8 hour' | genotype, infect, time | RNA-Seq of SOX4 and HOXD3 CRISPR KO SupT1 cells against wildtype SupT1 cells during HIV-1 infection |
1.6 | | CHRNA3 | 'heat shock' vs 'untreated' | growth condition | RNA-seq analysis of U2OS cells exposed to heat stress |
-1.6 | | CHRNA3 | 'dexamethasone; 1 micromolar' vs 'vehicle' | compound | RNA-seq in GR18 cell line to identify genes regulated by the Glucocorticoid Receptor (24h treatment) |
1.6 | | CHRNA3 | 'blood alcohol content 0%' vs 'control' in 'time point 1' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
1.6 | | CHRNA3 | 'blood alcohol content 0.04%declining' vs 'control' in 'time point 4' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
1.6 | | CHRNA3 | '200 nanomolar retinoic acid' vs 'none' | compound | Transcription profiling by array of human embryonic stem cells response to retinoic acid exposure |
1.6 | | CHRNA3 | '2 micromolar; retinoic acid' vs '1 micromolar DMSO' | compound | Transcription profiling by array of human embryonic stem cells response to retinoic acid exposure |
1.6 | | CHRNA3 | 'transfection with GFP-FOXP3 cDNA' vs 'transfection with GFP cDNA' | genetic modification | Transcription profiling by array of human LNCaP cells transfected with GFP-FOXP3 cDNA |
-1.6 | | CHRNA3 | 'MCT8[P321L]' vs 'wild type genotype' in 'derived brain microvascular endothelial cell' | cell type, compound, genotype | RNA-seq analysis of MCT8-deficient and healthy control brain microvascular endothelial cells (BMECs) and neural cells |
-1.6 | | CHRNA3 | 'MCT8[P321L]' vs 'correction to MCT8[wt]' in 'derived brain microvascular endothelial cell' | cell type, compound, genotype | RNA-seq analysis of MCT8-deficient and healthy control brain microvascular endothelial cells (BMECs) and neural cells |
-1.6 | | CHRNA3 | 'tumor necrosis factor alpha' vs 'none' in 'astrocyte; co-culture' | cell type, growth condition, stimulus | Reactive astrocytes transduce blood-brain barrier inflammation through a TNFα-STAT3 signaling axis and secretion of alpha 1-antichymotrypsin |
1.5 | | CHRNA3 | 'embryonic stem cell differentiating toward definitive endoderm; 48 hour' vs 'embryonic stem cell; 0 hour' | cell type, time | RNA-seq of definitive endoderm differentiation of human embryonic stem cells in early G1 phase of the cell cycle |
1.5 | | CHRNA3 | 'blood alcohol content 0.08%' vs 'control' in 'time point 3' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
1.5 | | CHRNA3 | 'blood alcohol content 0.02%declining' vs 'control' in 'time point 5' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
1.5 | | CHRNA3 | '2 micromolar retinoic acid' vs 'none' | compound | Transcription profiling by array of human embryonic stem cells response to retinoic acid exposure |
-1.5 | | CHRNA3 | 'Ataxia-telangiectasia' vs 'normal' | disease | Ataxia-telangiectasia cerebellar cortex expression |
-1.5 | | CHRNA3 | 'Crohn's disease; B3, penetrating' vs 'non inflammatory bowel disease control' | disease, disease staging | mRNA and small RNA associated with Crohn's disease behavior [RNA-Seq] |
-1.5 | | CHRNA3 | 'RRx-1; 20 micromolar' vs 'none' | compound | RNA-seq of Huh7 cell after G6PD enzyme activity inhibitor RRx-1 treated with 20μM concentrations for 24h |
1.4 | | CHRNA3 | 'lesion' vs 'normal tissue adjacent to lesion' in '1 week' | sampling site, time | RNA-sequencing of the mRNA transcriptome in lesional and non-lesional skin, across three time-points in severe psoriasis patients treated with the tumor necrosis factor (TNF) inhibitor, etanercept |
1.4 | | CHRNA3 | '4 day' vs '0 day' | time | RNA-Seq characterization of human H1-derived NPC differentiation timecourse |
-1.4 | | CHRNA3 | 'Zika virus' vs 'control' | infect | Transcription profiling by high throughput sequencing of Zika virus-infected human brain organoids |
1.4 | | CHRNA3 | 'psoriasis lesional skin' vs 'psoriasis non-lesional skin' | clinical information | Gene expression profiling in psoriatic lesional and non-lesional skin [Set 1] |
-1.4 | | CHRNA3 | 'xenografted under NOD-scid/IL2Rg-null mouse kidney capsule for 10 weeks' vs 'not applicable' in 'organoid culture in alginate gel' | growth condition, xenograft | Epithelium-only cultured stem cells isolated from human pluripotent stem cell derived intestinal organoids grown in matrigel and alginate |
-1.4 | | CHRNA3 | 'non-small cell lung carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
1.3 | | CHRNA3 | 'psoriasis; lesional skin' vs 'normal; normal' | disease, phenotype | Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides insights into disease mechanisms |
1.3 | | CHRNA3 | 'DISC1 exon 8 wt/mut' vs 'wild type' in 'neural progenitor cell' at 'embryoid body, day 17' | cell type, genotype, sampling time point | Transcriptome profiling of human neural progenitor cells and neurons with DISC1 interruption |
1.3 | | CHRNA3 | '6 to 8 weeks post ovulation' vs 'adult' in 'normal' | developmental stage, disease | Comparison of gene expression profiling of human lung at four developmental stages and lung adenocarcioma |
-1.3 | | CHRNA3 | 'OTX015; 500 nanomolar' vs 'dimethyl sulfoxide' | compound | Transcription profiling by array of IMR-5 neuroblastoma cells treated with bromodomain-containing protein 4 (BRD4) inhibitor OTX015 |
1.3 | | CHRNA3 | 'blood alcohol content 0.04%rising' vs 'control' in 'time point 2' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
1.3 | | CHRNA3 | 'kidney transplant; transplant rejection; acute' vs 'none; normal; none' | clinical information, disease, disease staging | Expression of the IL-17/Th17 axis in the development of acute renal allograft rejection |
-1.3 | | CHRNA3 | 'definitive endoderm differentiated from H9 stem cells' vs 'Undifferentiated H9 Stem Cells' | cell type | Transcriptional Profiling of human pluripotent stem cells and and derived tissues |
1.3 | | CHRNA3 | 'transplant rejection; acute' vs 'normal; none' in 'kidney transplant' | clinical information, disease, disease staging | Expression of the IL-17/Th17 axis in the development of acute renal allograft rejection |
1.3 | | CHRNA3 | 'psoriasis lesional skin' vs 'psoriasis non-lesional skin' | clinical information | Gene expression in psoriasis lesions and uninvolved skin |
-1.3 | | CHRNA3 | 'glioblastoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-1.2 | | CHRNA3 | '60 hour' vs '48 hour' in 'embryonic stem cell differentiating toward definitive endoderm' | cell type, time | RNA-seq of definitive endoderm differentiation of human embryonic stem cells in early G1 phase of the cell cycle |
1.2 | | CHRNA3 | 'Cisplatin' vs 'None' in 'A2780cis; Normoxia' | cell line, compound, growth condition | Analysis of gene expression changes in response to hypoxia and/or cisplatin in A2780 and A2780cis cells |
1.2 | | CHRNA3 | 'cultured skin substitute; 28 day' vs 'skin; 0 day' | organism part, time | Transcription profiling by array of human grafted engineered skin substitutes |
-1.2 | | CHRNA3 | 'SPI1 -/-' vs 'SPI1 +/+' | genotype | RNA-seq of RS4:11 cell line populations that are unedited (SPI1 +/+), mono (SPI1 +/-) and biallelicaly edited (SPI1 -/-) |
1.2 | | CHRNA3 | 'contrast-enhancing core; glioma' vs 'normal' | biopsy site, disease | Transcription profiling by high throughput sequencing in the margins of glioblastoma |
-1.1 | | CHRNA3 | 'SNCA overexpression' vs 'wild type genotype' | genotype | RNA-seq of human midbrain organoid models of Parkinson's Disease |
-1.1 | | CHRNA3 | 'THZ1 (35 nanomolar)' vs 'none' | compound | RNA-seq of IMR-5/75 neuroblastoma cell line treated with JQ1, THZ1 or combination against untreated controls |
1.1 | | CHRNA3 | 'lesion' vs 'normal tissue adjacent to lesion' in '12 week' | sampling site, time | RNA-sequencing of the mRNA transcriptome in lesional and non-lesional skin, across three time-points in severe psoriasis patients treated with the tumor necrosis factor (TNF) inhibitor, etanercept |
-1.1 | | CHRNA3 | 'JQ1; 500 nanomolar' vs 'dimethyl sulfoxide' | compound | Transcription profiling by array of IMR-5 neuroblastoma cells treated with bromodomain-containing protein 4 (BRD4) inhibitor OTX015 |
1.1 | | CHRNA3 | '2 day' vs '0 day' | time | RNA-Seq characterization of human H1-derived NPC differentiation timecourse |
1.1 | | CHRNA3 | 'differentiated; hAKPC-P' vs 'undifferentiated; hIPod' | cell type, phenotype | Differentiation of human amniotic fluid kidney progenitor cells into podocytes and comparison with human conditionally immortalized podocytes |
1.1 | | CHRNA3 | 'suberoylanilide hydroxamic acid 10 millimolar' vs 'none' | compound, dose | Transcription profiling by array of A204 cells after treatment with SAHA |
-1.1 | | CHRNA3 | 'epithelial-to-mesenchymal transition' vs 'normal' | phenotype | Gene expression from H69M versus H69 SCLC cell lines |
1.1 | | CHRNA3 | 'transplant rejection; borderline' vs 'normal; none' in 'kidney transplant' | clinical information, disease, disease staging | Expression of the IL-17/Th17 axis in the development of acute renal allograft rejection |
1.1 | | CHRNA3 | 'kidney transplant; transplant rejection; borderline' vs 'none; normal; none' | clinical information, disease, disease staging | Expression of the IL-17/Th17 axis in the development of acute renal allograft rejection |
-1.1 | | CHRNA3 | 'MOLT-4; acute lymphoblastic leukemia; P10' vs 'MOLT-4; acute lymphoblastic leukemia; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
-1.1 | | CHRNA3 | 'MCT8[A404fs416X]' vs 'wild type genotype' in 'derived brain microvascular endothelial cell' | cell type, compound, genotype | RNA-seq analysis of MCT8-deficient and healthy control brain microvascular endothelial cells (BMECs) and neural cells |
1.1 | | CHRNA3 | 'medulloblastoma, large-cell' vs 'normal' | disease | Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes |
-1.1 | | CHRNA3 | 'subependymal giant cell astrocytoma' vs 'normal' | disease | Transcription profiling by array of human subependymal giant cell astrocytoma brain tumors |
1 | | CHRNA3 | 'lesional' vs 'non-lesional' | clinical information | Expression data from skin biopsy samples from patients with moderate-to-severe psoriasis |
1 | | CHRNA3 | 'WTAP shRNA' vs 'none' in 'SB-431542; 10 micromolar' at '32 hour' | RNA interference, compound, time | RNA-seq of WTAP knockdown human pluripotent stem cells during the exit from pluripotency induced by Activin/Nodal inhibition |
1 | | CHRNA3 | 'WTAP shRNA' vs 'none' in 'Activin A; 10 nanogram per milliliter' at '2 hour' | RNA interference, compound, time | RNA-seq of WTAP knockdown human pluripotent stem cells during the exit from pluripotency induced by Activin/Nodal inhibition |
-1 | | CHRNA3 | 'brain-derived neurotrophic factor' vs 'none' at '12 hour' | sampling time point, stimulus | RNA-seq of human neurons derived from H9 embryonic stem cell lines treated with BDNF, TrkB agonist ZEB 85 or NT4 against untreated controls |
1 | | CHRNA3 | 'osteosarcoma' vs 'normal' | disease | Transcription profiling by array of human bone specimens from patients with osteosarcoma |
-1 | | CHRNA3 | 'neurotrophin-4' vs 'none' at '12 hour' | sampling time point, stimulus | RNA-seq of human neurons derived from H9 embryonic stem cell lines treated with BDNF, TrkB agonist ZEB 85 or NT4 against untreated controls |
1 | | CHRNA3 | 'differentiated; hAKPC-P' vs 'undifferentiated; hAKPC-P' | cell type, phenotype | Differentiation of human amniotic fluid kidney progenitor cells into podocytes and comparison with human conditionally immortalized podocytes |
1 | | CHRNA3 | 'differentiated; hAKPC-P' vs 're-differentiated; hIPod' | cell type, phenotype | Differentiation of human amniotic fluid kidney progenitor cells into podocytes and comparison with human conditionally immortalized podocytes |
-1 | | CHRNA3 | 'MOLT-4; acute lymphoblastic leukemia; P04' vs 'MOLT-4; acute lymphoblastic leukemia; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
-1 | | CHRNA3 | 'T3; 100 nanomolar' vs 'none' in 'derived neural cell; induced MCT8 mutation' | cell type, compound, genotype | RNA-seq analysis of MCT8-deficient and healthy control brain microvascular endothelial cells (BMECs) and neural cells |
1 | | CHRNA3 | 'HES1 homozygous knockout' vs 'wild type genotype' | genotype | RNA-seq of Human Embryonic Stem Cell derived pancreas progenitor differentiation, Day 13 of wildtype, HES1-/-, NEUROG3-/- and HES1-/-NEUROG3-/- genotypes |
1 | | CHRNA3 | 'gestational week 11 to 13' vs 'adult' in 'normal' | developmental stage, phenotype | Comparison of global gene expression profiles of microdissected human foetal Leydig cells with their normal and hyperplastic adult equivalents |
-1 | | CHRNA3 | 'organoid culture in matrigel' vs 'organoid culture in alginate gel' in 'not applicable' | growth condition, xenograft | Epithelium-only cultured stem cells isolated from human pluripotent stem cell derived intestinal organoids grown in matrigel and alginate |
